FDA Announces Updated Warnings for Ampyra Users
Aug. 10, 2012
The US Food and Drug Administration (FDA) recently announced a warning label update for the drug, Ampyra, which is often taken by patients with Multiple Sclerosis (MS). According to an FDA press release, the update was made after numerous patients reported having seizures as a result of taking the drug.
The drug was approved in January 2010 and has been dispensed to more than 46,000 patients across the nation. It works by increasing neuronal function and activity in a patient’s limbs, thereby improving their mobility.
Ampyra becomes dangerous to take when patients show signs of high blood pressure or kidney impairment, which can present a risk of drug injuries,. Patients with these conditions who take a high dosage of the medication could be at risk of suffering a seizure.
The updated warning labels will be required to state clearly on the box that there is a seizure risk while also warning users that kidney function should be tested annually while on the medication. Furthermore, patients who miss a dose will be advised not to take double dose when they next medicate, as this significantly raises the chances of suffering a seizure.
The Colorado Personal Injury Lawyers at the McDivitt Law Firm have helped many victims of drug injuries get back on their feet after a medication error and would encourage anyone who has suffered a Colorado drug injury to contact an experienced attorney to discuss their legal rights.Back to the Blog